Creative Medical Technology Holdings, Inc. cash flow statement
In fiscal 2025, Creative Medical Technology Holdings, Inc.'s operations generated −$5.9m of cash. It returned $10,000 through buybacks.
Cash flow statement
| Fiscal year | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −1 | −1 | −1 | −0 | −2 | −8 | −8 | −5 | −6 | −6 |
| Depreciation and amortisation | — | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 0 | — | — |
| Stock-based pay | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | — | — | — | — | — | — | — | — | — | — | — | — | 0 | 0 | 0 | 0 | 0 |
| Shares issued | — | — | — | — | — | — | 1 | 0 | 0 | — | 0 | 15 | 15 | 0 | 2 | 7 | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −986 | −1,950 | −1,592 | −1,159 | −1,169 | −1,938 | −1,323 | −1,472 |
| Depreciation and amortisation | 0 | 10 | 46 | — | — | — | — | — |
| Stock-based pay | 9 | 9 | 3 | 0 | 0 | 0 | 0 | 0 |
| Shares issued | — | — | 3,364 | 0 | — | — | 0 | 4,465 |
Compare with peers
- Lyell Immunopharma, Inc. cash flow
- AIM Immunotech Inc. cash flow
- Ibio, Inc. cash flow
- Lisata Therapeutics, Inc. cash flow
- Celldex Therapeutics, Inc. cash flow
Head to head: CELZ vs LYELAIM vs CELZCELZ vs IBIO
More: Biotechnology stocks compared, Health Care sector, rankings of US companies